Arbutus Biopharma (ABUS) Assets (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Assets for 17 consecutive years, with $277.2 million the latest figure, recorded in Q1 2026.

• Quarterly Assets rose 136.87% year-over-year to $277.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $277.2 million (up 136.87% YoY) and the FY2025 annual result came in at $94.6 million, down 28.16% from the prior year.
• Assets advanced to $277.2 million in Q1 2026 per ABUS's latest filing, from $94.6 million in the prior quarter.
• Over the last five years, Assets for ABUS reached as high as $277.2 million in Q1 2026 and fell as low as $94.6 million in Q4 2025.
• A 5-year average of $164.4 million and a median of $158.6 million in 2023 frame the typical range for Assets.
• Annual changes were most pronounced in 2025 — Assets plunged 35.48% — and 2026, when it soared 136.87%.
• Year by year, Assets stood at $195.4 million in 2022, then decreased by 26.11% to $144.4 million in 2023, then retreated by 8.79% to $131.7 million in 2024, then slipped by 28.16% to $94.6 million in 2025, then jumped by 192.93% to $277.2 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $277.2 million, $94.6 million, and $97.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.